Chris Markoch

Chris Markoch

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Naked Brand Group is Not Safe For Investors

NAKD stock is in danger of being delisted despite the company's efforts to compete in a niche that is saturated with competition.

General Electric Is Still Playing a Losing Hand

General Electric has thrown everything into rebuilding itself. But for GE stock to be credible again, the economy has to pick up substantively.

Apple’s Price and Value Aren’t Matching Now

AAPL stock continues to shake off its March selloff, but store closures are a reminder that the pandemic is still creating uncertainty.

A Vaccine Is The Only Thing That Can Help United Airlines

Traffic statistics and fundamentals are largely irrelevant until passengers feel safe and that's bad news for United Airlines stock.

Alibaba Stock Is A Buy No Matter Who the President Might Be

Alibaba is a global powerhouse that mirrors multiple FAANG stocks in a single entity. So why doesn't BABA stock trade higher?

Virgin Galactic Can’t Hype Away Lousy Math

Virgin Galactic's recent agreement with NASA has day traders bidding up SPCE stock. However, wait until the stock delivers on the hype.

What is Your (New) Ceiling for Nio Stock?

With liquidity fears behind it, Nio stock is on a tear. While being solvent is an encouraging feat, the company must now show it can grow.

3 Pumped-Up Gym Stocks to Help Power Your Portfolio

Americans are eager to get back into shape after being locked down for months from the coronavirus. Here are three gym stocks to buy.

The Future Could Be Soon for Crispr Therapeutics

Patient investors can finally receive their rewards if Crispr Therapeutics makes good on its gene-editing breakthrough. However, you've got to be in CRISPR stock before this occurs.

The Sad News About Southwest’s Solid Balance Sheet

Investors are doing their best to see the best possible news for Southwest Airlines. But LUV stock still faces a slow recovery.